E J Topol

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Diabetes mellitus: biological determinants of atherosclerosis and restenosis
    S P Marso
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Interv Cardiol 4:129-43. 1999
  2. ncbi request reprint Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 103:961-6. 2001
  3. pmc Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
    H S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Heart 89:1200-4. 2003
  4. ncbi request reprint Platelet GPIIb-IIIa blockers
    E J Topol
    Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    Lancet 353:227-31. 1999
  5. ncbi request reprint Role of platelets in restenosis after percutaneous coronary revascularization
    H Le Breton
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195 5066, USA
    J Am Coll Cardiol 28:1643-51. 1996
  6. ncbi request reprint Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complicatio
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 278:479-84. 1997
  7. ncbi request reprint Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
    J G Peterson
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 87:532-6. 2001
  8. ncbi request reprint Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    D L Bhatt
    Department of Cardiology, F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 284:1549-58. 2000
  9. ncbi request reprint beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2685-8. 2001
  10. ncbi request reprint Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries
    D B Brieger
    Department of Cardiology and the Joseph J Jacobs Center for Vascular Biology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 81:282-7. 1998

Detail Information

Publications67

  1. ncbi request reprint Diabetes mellitus: biological determinants of atherosclerosis and restenosis
    S P Marso
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Interv Cardiol 4:129-43. 1999
    ..This review will focus in the underlying patho-biology and the current status of therapeutic interventional strategies for patients with diabetes mellitus...
  2. ncbi request reprint Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 103:961-6. 2001
    ....
  3. pmc Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
    H S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Heart 89:1200-4. 2003
    ..An increase in the white blood cell (WBC) count is a non-specific response to inflammation. We hypothesised that a raised baseline WBC count would be a predictor of mortality in patients undergoing PCI...
  4. ncbi request reprint Platelet GPIIb-IIIa blockers
    E J Topol
    Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    Lancet 353:227-31. 1999
    ..With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required...
  5. ncbi request reprint Role of platelets in restenosis after percutaneous coronary revascularization
    H Le Breton
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195 5066, USA
    J Am Coll Cardiol 28:1643-51. 1996
    ..Considerable further study is necessary to unravel the effects of platelets on the restenosis process...
  6. ncbi request reprint Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complicatio
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 278:479-84. 1997
    ..A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months...
  7. ncbi request reprint Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
    J G Peterson
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 87:532-6. 2001
    ..31, 95% CI 0.10 to 0.93, p = 0.04). Thus, the apparent positive impact of heparin on the benefits of eptifibatide therapy was largely due to confounding and bias...
  8. ncbi request reprint Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    D L Bhatt
    Department of Cardiology, F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 284:1549-58. 2000
    ..Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are potent inhibitors of platelet function that may be expected to affect favorably the natural history of ACSs...
  9. ncbi request reprint beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2685-8. 2001
    ..The cogency of such a conclusion is dependent on the ability to risk-adjust for the multiple differences in patients treated with and without BBs...
  10. ncbi request reprint Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries
    D B Brieger
    Department of Cardiology and the Joseph J Jacobs Center for Vascular Biology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 81:282-7. 1998
    ....
  11. ncbi request reprint Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
    E J Topol
    Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA
    Lancet 357:1905-14. 2001
    ..We did a randomised, open-label trial to compare the effect of reteplase alone with reteplase plus abciximab in patients with acute myocardial infarction...
  12. ncbi request reprint Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    N Engl J Med 344:1888-94. 2001
    ..We assessed whether there are differences in safety or efficacy between two such inhibitors, tirofiban and abciximab...
  13. ncbi request reprint The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics
    S P Marso
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 33:1269-77. 1999
    ..The aims of this study were to compare mortality and clinical events following percutaneous coronary intervention (PCI) between nondiabetics and diabetics with and without proteinuria...
  14. ncbi request reprint Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Out
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 32:1619-23. 1998
    ....
  15. ncbi request reprint Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 104:992-7. 2001
    ..Coupled anatomic, clinical, and inflammatory risk stratification demonstrates strong predictive utility among patients undergoing percutaneous coronary intervention and may be useful for guiding future strategies...
  16. ncbi request reprint Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial
    S J Brener
    Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 84:728-30, A8. 1999
    ..Abciximab significantly reduced the time-to-peak creatine kinase without affecting enzymatic infarct size, suggesting a beneficial effect on the pattern and speed of reperfusion...
  17. ncbi request reprint Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting
    S P Marso
    Department of Cardiology, The Cleveland Clinic Foundation, OH, USA
    Am Heart J 139:939-44. 2000
    ..We hypothesized that diabetic patients with evidence of proteinuria would have increased mortality and clinical event rates after isolated coronary artery bypass grafting compared with nonproteinuric diabetic patients...
  18. ncbi request reprint Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
    H D Aronow
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Lancet 357:1063-8. 2001
    ..67 [0.48-0.95], p=0.023). INTERPRETATION: Prescription of a lipid-lowering drug at hospital discharge was independently associated with reduced short-term mortality among patients after an acute coronary syndrome...
  19. ncbi request reprint Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 100:1977-82. 1999
    ..Diabetic patients in particular are a subgroup of patients with known underlying platelet abnormalities whose long-term response to abciximab has been shown to vary from that of nondiabetic patients...
  20. ncbi request reprint Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction
    E J Topol
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2641-4. 2001
    ..Recent advances in high-throughput genomics technology have expanded our ability to catalogue allelic variants in large sets of candidate genes related to premature coronary artery disease...
  21. ncbi request reprint Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
    A M Lincoff
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Circulation 104:163-7. 2001
    ..001); and the rise in tumor necrosis factor-alpha levels was 100% less with abciximab therapy (P=0.112). By 4 weeks, most marker levels had returned to baseline, with no significant differences between placebo and abciximab groups...
  22. ncbi request reprint Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, OH 44195, USA
    J Am Coll Cardiol 31:1306-13. 1998
    ..We sought to determine the clinical, angiographic, treatment and outcome correlates of the intermediate-term cost of caring for patients with suspected coronary artery disease (CAD)...
  23. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes
    M Roffi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2767-71. 2001
    ..Therefore, the use of platelet GP IIb/IIIa inhibitors should be strongly considered in diabetic patients with ACS...
  24. ncbi request reprint Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Lancet 354:2019-24. 1999
    ..We assessed in a randomised trial the long-term outcomes for potent adjunctive antiplatelet therapy given at the time of coronary stenting...
  25. ncbi request reprint A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study
    D J Moliterno
    Department of Cardiology and the Cleveland Clinic Cardiovascular Coordinating Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 140:722-6. 2000
    ..All trials were placebo-controlled, and none involved a direct comparison of IIb/IIIa inhibitors. Whether these agents produce a similar clinical outcome in the contemporary practice of coronary interventions is uncertain...
  26. ncbi request reprint Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial
    E J Topol
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 102:1761-5. 2000
    ..One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial...
  27. ncbi request reprint Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
    E J Topol
    Department of Cardiology, The Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 139:927-33. 2000
    ..More effective antithrombotic agents are still required to treat patients at high risk for recurrent vascular events...
  28. ncbi request reprint Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
    D L Bhatt
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 103:363-8. 2001
    ..CONCLUSION:Compared with aspirin, clopidogrel therapy results in a striking reduction in the elevated risk for recurrent ischemic events seen in patients with a history of prior cardiac surgery, along with a decreased risk of bleeding...
  29. ncbi request reprint Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction
    F A Cura
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 88:124-8. 2001
    ..Conversely, the presence of normal or near-normal coronary flow before intervention correlates with a good angiographic result. Mortality risk is increased in patients with postprocedural suboptimal angiographic coronary flow...
  30. ncbi request reprint Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting
    D L Bhatt
    Department of Cardiology, F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA
    J Invasive Cardiol 13:767-71. 2001
    ..Furthermore, clopidogrel appears superior to ticlopidine. Thus, our findings lend support to the dual antiplatelet strategy of clopidogrel plus aspirin for patients undergoing carotid artery stenting...
  31. ncbi request reprint Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results
    S G Ellis
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 33:1278-85. 1999
    ..We sought to evaluate methodologies to compare physician-related long-term patient outcomes appropriately...
  32. ncbi request reprint Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification scheme
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 100:1971-6. 1999
    ..Major advances in treatment options would suggest that this scheme may be outmoded, but the schemes that have been suggested to update lesion classification have not been widely accepted...
  33. ncbi request reprint Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 103:1403-9. 2001
    ..The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored...
  34. ncbi request reprint Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis
    F A Nicolini
    Department of Cardiology, Joseph J Jacobs Center for Thrombosis and Vascular Biology, Cleveland, Ohio, USA
    Blood Coagul Fibrinolysis 7:39-48. 1996
    ..These findings highlight the potential adverse effects of unchecked thrombin generation in the setting of thrombolytic therapy...
  35. ncbi request reprint Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Prog Cardiovasc Dis 44:195-206. 2001
    ..Consideration of these factors may facilitate the optimal clinical application of this class of agents to the management of coronary instability...
  36. ncbi request reprint Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 103:201-6. 2001
    ..These findings suggest the potential for a direct toxic effect with these agents and argue against a prothrombotic mechanism. Further investigation to elucidate the cause of this increased fatality risk is warranted...
  37. ncbi request reprint Common variations in platelet glycoproteins: pharmacogenomic implications
    M J Quinn
    Department of Cardiovascular Medicine, Desk F 25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Pharmacogenomics 2:341-52. 2001
    ..These discoveries have stimulated interest in the role of genetic factors in platelet physiology. In this article, the current knowledge of the influence of genetic make-up on antiplatelet therapy is discussed...
  38. ncbi request reprint Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex 78236 5300, USA
    JAMA 281:806-10. 1999
    ....
  39. ncbi request reprint Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for O
    E B Sgarbossa
    Cleveland Clinic Foundation, Ohio, USA
    J Am Coll Cardiol 31:105-10. 1998
    ..We sought to assess the outcome of patients with acute myocardial infarction (MI) and bundle branch block in the thrombolytic era...
  40. ncbi request reprint Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus
    S H Park
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195-5066, USA
    Circulation 104:815-9. 2001
    ..The obese Zucker rat model may be an ideal diabetic model to further characterize the diabetic vascular response to injury...
  41. ncbi request reprint Profile and prevalence of aspirin resistance in patients with cardiovascular disease
    P A Gum
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 88:230-5. 2001
    ..7 vs 61.3 years, p = 0.06). There were no differences in aspirin sensitivity by race, diabetes, platelet count, renal disease, or liver disease...
  42. ncbi request reprint Oral glycoprotein IIb/IIIa inhibitors: why don't they work?
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 1:421-8. 2001
    ..Definitive elucidation of these adverse mechanisms will be required if further clinical development of the oral platelet glycoprotein IIb/IIIa inhibitors is to be pursued...
  43. ncbi request reprint Frequency and long-term impact of myonecrosis after coronary stenting
    S J Brener
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Eur Heart J 23:869-76. 2002
    ..To study the frequency of creatine kinase MB elevation in stent recipients and to correlate the magnitude of myonecrosis with long-term ischaemic events...
  44. pmc Four SNPS on chromosome 9p21 confer risk to premature, familial CAD and MI in an American Caucasian population (GeneQuest)
    K G Abdullah
    Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
    Ann Hum Genet 72:654-7. 2008
    ..Sib-TDT analysis showed that three of the four SNPs could confer significant susceptibility to premature CAD and MI. These results indicate that the four SNPs on chromosome 9p21 are also associated with premature, familial CAD...
  45. ncbi request reprint Glycoprotein IIb/IIIa antagonists--from bench to practice
    I P Casserly
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Cell Mol Life Sci 59:478-500. 2002
    ..Such studies may also hold the key to the development of newer agents with enhanced therapeutic benefit...
  46. ncbi request reprint Association between myeloperoxidase levels and risk of coronary artery disease
    R Zhang
    Department of Cell Biology, Cleveland Clinic Foundation, 9500 Euclid Ave, NC-10, Cleveland, OH 44195, USA
    JAMA 286:2136-42. 2001
    ..These findings support a potential role for MPO as an inflammatory marker in CAD and may have implications for atherosclerosis diagnosis and risk assessment...
  47. ncbi request reprint Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model
    K Wang
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 38:577-82. 2001
    ....
  48. ncbi request reprint Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy
    K Kottke-Marchant
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Eur Heart J 23:1202-12. 2002
    ..We compared the effects of hirudin and heparin on thrombin generation and activity among 350 patients with acute coronary syndromes enrolled in the GUSTO-IIb trial...
  49. ncbi request reprint Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial
    S Savonitto
    Department of Cardiology, Niguarda Hospital, Milan, Italy
    Eur Heart J 24:1807-14. 2003
    ....
  50. ncbi request reprint The early history and development of thrombolysis in acute myocardial infarction
    A Maroo
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Thromb Haemost 2:1867-70. 2004
  51. pmc Fibrinolytic treatment for elderly patients with acute myocardial infarction
    J M Estess
    Heart 87:308-11. 2002
  52. doi request reprint Facilitated PCI in patients with ST-elevation myocardial infarction
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, F25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    N Engl J Med 358:2205-17. 2008
    ....
  53. pmc The ECG in acute coronary syndromes: new tricks from an old dog
    H S Gurm
    Heart 91:851-3. 2005
    ..The ECG remains the pre-eminent test for myocardial ischaemia, directing therapeutic management and prognostic stratification...
  54. pmc Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk
    D P Chew
    Flinders University, Adelaide, South Australia, Australia
    Heart 92:945-50. 2006
    ..To explore the relative and absolute risks associated with various definitions for myocardial infarction, bleeding and revascularisation within the context of percutaneous coronary intervention (PCI)...
  55. ncbi request reprint Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making
    L K Newby
    The Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    Eur Heart J 24:182-9. 2003
    ..We evaluated timing of adverse cardiac events after thrombolysis to guide length of stay after ST-segment elevation myocardial infarction...
  56. ncbi request reprint Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT
    L Cho
    Department of Cardiology and Biostatistics, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Am Heart J 141:599-602. 2001
    ..03). CONCLUSIONS: This pooled analysis demonstrates that after PCI, smokers had worse 30-day outcomes than did nonsmokers. However, both groups had a comparable degree of benefit with platelet inhibition through the use of abciximab...
  57. pmc Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease
    J J McCarthy
    J Med Genet 40:453-8. 2003
  58. pmc The primacy of clinical effectiveness for cost effectiveness analysis
    I P Casserly
    Heart 89:249-50. 2003
  59. ncbi request reprint Recurrent ischemia after thrombolysis for acute myocardial infarction
    L Pilote
    Montreal General Hospital, Montreal, Quebec, Canada
    Am Heart J 141:559-65. 2001
    ..Early coronary angiography reduces recurrent ischemia, probably because high-risk patients are identified and revascularized...
  60. ncbi request reprint Predictors of 90-day outcome in patients stabilized after acute coronary syndromes
    L K Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    Eur Heart J 24:172-81. 2003
    ..We investigated predictors of 90-day risk among patients surviving the early period after an acute coronary syndrome (ACS)...
  61. pmc Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries
    C K Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Heart 88:357-62. 2002
    ..To investigate the use of antiarrhythmic agents and electrical cardioversion in the management of patients with atrial fibrillation complicating acute myocardial infarction, and their relation to 30 day and one year mortality...
  62. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy
    M Roffi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 441995, USA
    Eur Heart J 23:1441-8. 2002
    ..To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed...
  63. ncbi request reprint Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network
    P Kaul
    University of Alberta, Edmonton, Canada
    J Am Coll Cardiol 38:64-71. 2001
    ..CONCLUSIONS: These data provide new evidence supporting the powerful prognostic value of the baseline electrocardiogram and, in particular, the magnitude and distribution of ST segment depression in predicting unfavorable events...
  64. ncbi request reprint Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 136:398-405. 1998
    ..Platelets play an important role in the natural history of acute myocardial infarction (AMI)...
  65. ncbi request reprint Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker
    E Ronner
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur Heart J 23:239-46. 2002
    ..Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients...
  66. ncbi request reprint Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression usin
    M A Lauer
    Borgess Research Institute, Kalamazoo, Michigan, USA
    Circulation 104:2772-7. 2001
    ..Conclusions- An increase in death or myocardial infarction occurs in the 12 hours after heparin discontinuation in patients with acute coronary syndromes. This rebound is attenuated by glycoprotein IIb/IIIa inhibition with eptifibatide...
  67. ncbi request reprint The TARGET trial: hit or miss?
    D J Moliterno
    Eur Heart J 23:835-7. 2002